Verastem Inc (NASDAQ:VSTM)

Friday’s trading has closed, but VSTM is being traded in the after-hours session. After-Hours quote »
8.33
Delayed Data
As of 4:00pm ET
 +0.34 / +4.26%
Today’s Change
6.78
Today|||52-Week Range
14.92
-8.86%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$264.8M

Company Description

Verastem, Inc. is a clinical biopharmaceutical company, which is focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells. The company is developing small molecule inhibitors of signaling pathways which includes Focal Adhesion Kinase (FAK), PI3K/mTOR and Wnt that are critical to cancer stem cell survival and proliferation. Verastem was founded by Richard H. Aldrich, Michelle Dipp, Piyush Gupta, Satish Jindal, Eric S. Lander, Robert F. Weinberg and Christoph H. Westphal on August 4, 2010 and is headquartered in Cambridge, MA.

Contact Information

Verastem, Inc.
215 First Street
Cambridge Massachusetts 02142-1213
P:(617) 252-9300
Investor Relations:
(617) 252-9314

Employees

Shareholders

Individual stakeholders32.51%
Mutual fund holders24.47%
Other institutional20.82%

Top Executives

Robert M. ForresterPresident, Chief Executive Officer & Director
Daniel W. PatersonChief Operating Officer
John B. GreenChief Financial Officer
Jonathan PachterVice President & Head-Research
Joanna C. HorobinChief Medical Officer

To view my watchlist

Not a member yet?

Sign up now for a free account